1st Quarter - Report

BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) for BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)

Firm
Client
Income
—
Expenses
$83,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Issues pertaining to the FDA drug approval process and agency funding - [FY14 Agriculture, Rural Development, Food and Drug Administration and Related Agencies subcommittee bill]

LobbyistCovered position, as disclosed
EMILY SHETTY New Legislative Director, Rep. Edolphus Towns

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Issues pertaining to access to quality care for blood cancer patients [HR 460, Patients Access to Treatments Act - all provisions]; [The Cancer Drug Coverage Parity Act - all provisions]

LobbyistCovered position, as disclosed
EMILY SHETTY New Legislative Director, Rep. Edolphus Towns

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 460 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.